abs

학술발표회초록보기

초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 09월 10일 16시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

제124회 대한화학회 학술발표회, 총회 및 기기전시회 안내 Leucine-Rich Repeat Kinase 2 (LRRK2) small molecular inhibitors for Parkinson’s disease (PD)

등록일
2019년 9월 9일 10시 13분 39초
접수번호
1967
발표코드
MEDI.P-284 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
발표시간
10월 17일 (목요일) 11:00~12:30
발표형식
포스터
발표분야
Medicinal Chemistry
저자 및
공동저자
Heeyeon Kang, Seonghyeon Sim1, Jee Hee Suh, Ge Hyeong Lee2,*
Korea Research Institute of Chemical Technology, Korea
1chemistry, Sogang University, Korea
2Center for Medicinal Chemistry, Korea Research Institute of Chemical Technology, Korea
Parkinson’s disease (PD) is a neurodegenerative disease having motor symptoms such as tremor, muscular rigidity, shuffling gait, stoop posture, and slowing of movement. Leucine-rich repeat kinase 2 (LRRK2) protein mutations have been reported a leading cause of Parkinson’s disease (PD). LRRK2 is a large (2,527 amino acids) multidomain with five putative domains and has composed of seven variants (LRRK2[G2019S], LRRK2[I2020T], LRRK2[S1761R], LRRK2[Y1699C], LRRK2[R1441C/G], and LRRK2[N1437H]) associated with the disease. Herein we will discuss the reported biological and chemical efforts for LRRK2 regulation. Since brain cells develop the disease, we looking forward to finding brain penetrant, highly potent and selective LRRK2 small molecules.

상단으로